Michael L. Meyers, M.D., Ph.D., is the CEO of Nuvalent, Inc., a biotechnology company focused on developing targeted therapies for cancer. With a solid educational background holding both an M.D. and a Ph.D., Dr. Meyers combines clinical experience with scientific...
Michael L. Meyers, M.D., Ph.D., is the CEO of Nuvalent, Inc., a biotechnology company focused on developing targeted therapies for cancer. With a solid educational background holding both an M.D. and a Ph.D., Dr. Meyers combines clinical experience with scientific expertise. He joined Nuvalent's board in October 2022 and took on the CEO role shortly after. Before Nuvalent, he held key positions in other biotechnology companies, including Syndax Pharmaceuticals and Johnson & Johnson, where he played major roles in developing treatments for oncology and other serious conditions. Interestingly, in 2023, Dr. Meyers reported zero compensation, which is unusual for someone in his position. This might reflect a strategy focused on aligning his interests with the long-term success of the company rather than cash bonuses. He is also a member of the Nominating and Corporate Governance Committee, indicating his involvement in shaping the company's leadership and direction. Dr. Meyers is recognized for his strong commitment to advancing innovative therapies, having dedicated his career to improving patient outcomes in serious diseases.